In particular, the LOX pro-peptide has been shown to decrease ERK and Akt signaling [133,134,135,136] by inhibiting FGF-2 signaling upstream of these pathways in pancreatic, breast and prostate cancer cells [133,135]. The gene discussed is LOX; the disease is prostate carcinoma.